Literature DB >> 7054119

Correlation between in vivo anti-Pseudomonas and anti-Candida activities and clearance of carbon by the reticuloendothelial system for various muramyl dipeptide analogs, using normal and immunosuppressed mice.

E B Fraser-Smith, R V Waters, T R Matthews.   

Abstract

A linear correlation coefficient analysis, comparing in vivo anti-infective and reticuloendothelial stimulating activity of several different analogs of N-acetylmuramyl-L-alanyl-D-isoglutamine (muramyl dipeptide) suggests that the macrophage is an important target cell for these immunomodulating compounds. The increase in protection against infections of Candida albicans or Pseudomonas aeruginosa in normal or immunosuppressed mice after treatment with 18 different glycopeptides was found to correlate with the degree of clearance of colloidal carbon particles from the blood by the reticuloendothelial system after treatment with the same muramyl dipeptide analogs. The compound which gave the greatest protection in all four assays was N-acetylmuramyl-L-alpha-aminobutyryl-D-isoglutamine followed by N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine. Both analogs were better than the parent muramyl dipeptide. Whether macrophage stimulation alone is responsible for the anti-infective properties of these compounds has not yet been determined.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7054119      PMCID: PMC351002          DOI: 10.1128/iai.35.1.105-110.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Quantitative study of the granulopectic activity of the reticulo-endothelial system. II. A study of the kinetics of the R. E. S. in relation to the dose of carbon injected; relationship between the weight of the organs and their activity.

Authors:  G BIOZZI; B BENACERRAF; B N HALPERN
Journal:  Br J Exp Pathol       Date:  1953-08

2.  Inhibition of macrophage migration by synthetic muramyl dipeptide.

Authors:  Y Yamamoto; S Nagao; A Tanaka; T Koga; K Onoue
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

3.  Effects of muramyl dipeptide treatment on resistance to infection with Toxoplasma gondii in mice.

Authors:  J L Krahenbuhl; S D Sharma; R W Ferraresi; J S Remington
Journal:  Infect Immun       Date:  1981-02       Impact factor: 3.441

4.  Muramyl dipeptide stimulation of particle clearance in several animal species.

Authors:  R V Waters; R W Ferraresi
Journal:  J Reticuloendothel Soc       Date:  1980-11

5.  Increased bone marrow production of granulocytes and mononuclear phagocytes induced by mycobacterial adjuvants: improved recovery of leukopoiesis in mice after cyclophosphamide treatment.

Authors:  W C Buhles; M Shifrine
Journal:  Infect Immun       Date:  1978-04       Impact factor: 3.441

6.  Activation of macrophages for enhanced release of superoxide anion and greater killing of Candida albicans by injection of muramyl dipeptide.

Authors:  N P Cummings; M J Pabst; R B Johnston
Journal:  J Exp Med       Date:  1980-12-01       Impact factor: 14.307

7.  Protective effect of muramyl dipeptide analogs against infections of Pseudomonas aeruginosa or Candida albicans in mice.

Authors:  E B Fraser-Smith; T R Matthews
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

8.  Effects of treatment with muramyl dipeptide and certain of its analogs on resistance to Listeria monocytogenes in mice.

Authors:  R C Humphres; P R Henika; R W Ferraresi; J L Krahenbuhl
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

9.  Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.

Authors:  I J Fidler; S Sone; W E Fogler; Z L Barnes
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

10.  Cellular resistance to infection.

Authors:  G B MACKANESS
Journal:  J Exp Med       Date:  1962-09-01       Impact factor: 14.307

View more
  19 in total

1.  Efficacy of interleukin-1 beta against systemic Candida albicans infections in normal and immunosuppressed mice.

Authors:  R A Pecyk; E B Fraser-Smith; T R Matthews
Journal:  Infect Immun       Date:  1989-10       Impact factor: 3.441

2.  Protective effect of a muramyl dipeptide analog encapsulated in or mixed with liposomes against Candida albicans infection.

Authors:  E B Fraser-Smith; D A Eppstein; M A Larsen; T R Matthews
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

3.  Influence of preformed antibody on the pathogenesis of experimental Candida albicans endocarditis.

Authors:  W M Scheld; R A Calderone; J P Brodeur; M A Sande
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

4.  Stimulation of non-specific resistance to infections by synthetic immunoregulatory agents.

Authors:  M Parant; L Chedid
Journal:  Infection       Date:  1985       Impact factor: 3.553

5.  Stimulation of non-specific resistance to infections by synthetic immunoregulatory agents.

Authors:  M Parant; L Chedid
Journal:  Infection       Date:  1984 May-Jun       Impact factor: 3.553

6.  Formulation of vaccine adjuvant muramyldipeptides (MDP). 2. The thermal reactivity and pH of maximum stability of MDP compounds in aqueous solution.

Authors:  M F Powell; L C Foster; A R Becker; W Lee
Journal:  Pharm Res       Date:  1988-08       Impact factor: 4.200

7.  Anti-infectious activity of liposomal muramyl dipeptides in immunodeficient CBA/N mice.

Authors:  N C Phillips; L Chedid
Journal:  Infect Immun       Date:  1987-06       Impact factor: 3.441

8.  Problems in antifungal chemotherapy.

Authors:  D A Stevens
Journal:  Infection       Date:  1987 Mar-Apr       Impact factor: 3.553

9.  Prophylactic administration of interleukin-2 protects mice from lethal challenge with gram-negative bacteria.

Authors:  K T Chong
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

10.  Structure of Bordetella pertussis peptidoglycan.

Authors:  W J Folkening; W Nogami; S A Martin; R S Rosenthal
Journal:  J Bacteriol       Date:  1987-09       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.